Novavax, Inc.

Novavax, Inc.

$8.91
-0.27 (-2.94%)
NASDAQ Global Select
USD, US
Biotechnology

NVAX Price Chart

Basic
Market Cap$1.94B
Price$8.91
52 Week Range3.53-23.86
Beta2.04
Margins
Gross Profit Margin59.57%
Operating Profit Margin-34.74%
Net Profit Margin-35.77%
Valuation (TTM)
P/E Ratio-4.49
Price to Sales Ratio1.73
Price to Book Ratio-3.06
PEG Ratio-0.32

Industry

Biotechnology

Sector

Healthcare

Full-Time Employees

1,543

IPO Date

1995-12-05T00:00:00.000Z

Description

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Phone

240 268 2000

Address

21 Firstfield Road, Gaithersburg, MD, 20878, US

CIK

0001000694